Giovanni Targher

List of Publications by Citations

Source: https://exaly.com/author-pdf/4466641/giovanni-targher-publications-by-citations.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

488 papers	30,756 citations	85 h-index	163 g-index
543 ext. papers	37,774 ext. citations	6.6 avg, IF	7.82 L-index

#	Paper	IF	Citations
488	Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. *Diabetes Care*, **2000**, 23, 57-63	14.6	1906
487	Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. *New England Journal of Medicine*, **2010**, 363, 1341-50	59.2	1353
486	NAFLD: a multisystem disease. *Journal of Hepatology*, **2015**, 62, S47-64	13.4	1286
485	Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nature Reviews Gastroenterology and Hepatology*, **2013**, 10, 330-44	24.2	1022
484	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *Journal of Hepatology*, **2020**, 73, 202-209	13.4	764
483	Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. *Diabetes Care*, **2007**, 30, 1212-8	14.6	709
482	Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. *Diabetes*, **1998**, 47, 1643-9	0.9	647
481	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. *Journal of Hepatology*, **2016**, 65, 589-600	13.4	640
480	Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. *Gut*, **2017**, 66, 1138-1153	19.2	508
479	Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. *Diabetes*, **2005**, 54, 3541-6	0.9	449
478	Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. *Atherosclerosis*, **2007**, 191, 235-40	3.1	431
477	Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. *Diabetes Care*, **2007**, 30, 2119-21	14.6	395
476	HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. *Diabetes Care*, **2002**, 25, 1135-41	14.6	390
475	Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. *Journal of Gastroenterology and Hepatology (Australia)*, **2016**, 31, 936-44	4	378
474	Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?. *Diabetologia*, **2008**, 51, 1947-53	10.3	342
473	25-Hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the Third National Health and Nutrition Examination Survey. *Atherosclerosis*, **2009**, 205, 255-60	3.1	315
472	Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. *Diabetes Care*, **2006**, 29, 1325-30	14.6	312

471	Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?. *Journal of Hepatology*, **2018**, 68, 335-352	13.4	298
470	Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2007**, 17, 517-24	4.5	294
469	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. *Digestive and Liver Disease*, **2015**, 47, 997-1006	3.3	279
468	Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. *Diabetes Care*, **2018**, 41, 372-382	14.6	262
467	Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. *Diabetologia*, **2008**, 51, 444-50	10.3	242
466	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. *Journal of Clinical and Translational Hepatology*, **2020**, 8, 18-24	5.2	231
465	The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study. *Diabetic Medicine*, **2004**, 21, 52-8	3.5	213
464	Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with nonalcoholic fatty liver disease (the RAED2 Randomized Trial). *Hepatology*, **2013**, 58, 1287-95	11.2	211
463	Clinical Review: Nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. *Journal of Clinical Endocrinology and Metabolism*, **2013**, 98, 483-95	5.6	203
462	Serum 25-hydroxyvitamin D3 concentrations and prevalence of cardiovascular disease among type 2 diabetic patients. *Diabetes Care*, **2006**, 29, 722-4	14.6	200
461	Obesity Is a Risk Factor for Greater COVID-19 Severity. *Diabetes Care*, **2020**, 43, e72-e74	14.6	199
460	Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. *Clinical Endocrinology*, **2006**, 65, 593-7	3.4	198
459	Arterial thrombus formation in cardiovascular disease. *Nature Reviews Cardiology*, **2011**, 8, 502-12	14.8	180
458	AISF position paper on nonalcoholic fatty liver disease (NAFLD): Updates and future directions. *Digestive and Liver Disease*, **2017**, 49, 471-483	3.3	179
457	Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. *Journal of Hepatology*, **2009**, 51, 758-64	13.4	179
456	Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. *Journal of Hepatology*, **2010**, 53, 713-8	13.4	171
455	Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. *Metabolism: Clinical and Experimental*, **2018**, 79, 64-76	12.7	171
454	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. *Nature Reviews Endocrinology*, **2018**, 14, 99-114	15.2	170

453	Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. *Diabetic Medicine*, **2007**, 24, 1-6	3.5	170
452	Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. *Diabetes Care*, **2012**, 35, 99-104	14.6	167
451	Uric acid as a target of therapy in CKD. *American Journal of Kidney Diseases*, **2013**, 61, 134-46	7.4	165
450	The paradoxical relationship between serum uric acid and cardiovascular disease. *Clinica Chimica Acta*, **2008**, 392, 1-7	6.2	162
449	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. *World Journal of Gastroenterology*, **2014**, 20, 1724-45	5.6	160
448	Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. *Clinical Journal of the American Society of Nephrology: CJASN*, **2010**, 5, 2166-71	6.9	156
447	Non-alcoholic fatty liver disease and risk of cardiovascular disease. *Metabolism: Clinical and Experimental*, **2016**, 65, 1136-50	12.7	152
446	NASH predicts plasma inflammatory biomarkers independently of visceral fat in men. *Obesity*, **2008**, 16, 1394-9	8	152
445	Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. *Diabetes Care*, **2004**, 27, 2498-500	14.6	150
444	Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. *Nature Reviews Nephrology*, **2017**, 13, 297-310	14.9	146
443	Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. *Journal of the American Society of Nephrology: JASN*, **2008**, 19, 1564-70	12.7	143
442	Disorders of hemostasis associated with chronic kidney disease. *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 34-40	5.3	142
441	Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. *Clinical Endocrinology*, **2006**, 64, 679-83	3.4	141
440	Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. *Clinical Journal of the American Society of Nephrology: CJASN*, **2012**, 7, 401-8	6.9	138
439	Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. *Clinical Journal of the American Society of Nephrology: CJASN*, **2008**, 3, 1296-300	6.9	138
438	Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. *Diabetes Care*, **2012**, 35, 389-95	14.6	134
437	Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 3619-24	5.6	134
436	Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. *Diabetic Medicine*, **2005**, 22, 1354-8	3.5	134

435	Differences and similarities in early atherosclerosis between patients with non-alcoholic steatohepatitis and chronic hepatitis B and C. *Journal of Hepatology*, **2007**, 46, 1126-32	13.4	133
434	Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?. *Journal of Hepatology*, **2011**, 54, 1020-9	13.4	131
433	Intimal-medial thickness of the carotid artery in nondiabetic and NIDDM patients. Relationship with insulin resistance. *Diabetes Care*, **1997**, 20, 627-31	14.6	128
432	Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 1236-1248	4.5	126
431	Increased prevalence of cardiovascular disease in Type 2 diabetic patients with non-alcoholic fatty liver disease. *Diabetic Medicine*, **2006**, 23, 403-9	3.5	125
430	Moderate red wine consumption and cardiovascular disease risk: beyond the "French paradox". *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 59-70	5.3	122
429	Effects of glucosamine infusion on insulin secretion and insulin action in humans. *Diabetes*, **2000**, 49, 926-35	0.9	122
428	Psoriasis and the metabolic syndrome. *Clinics in Dermatology*, **2018**, 36, 21-28	3	120
427	CKD and nonalcoholic fatty liver disease. *American Journal of Kidney Diseases*, **2014**, 64, 638-52	7.4	120
426	Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **1996**, 16, 368-74	9.4	120
425	Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. *PLoS ONE*, **2013**, 8, e57183	3.7	119
424	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. *Gut*, **2020**, 69, 1691-1705	19.2	118
423	Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. *Diabetologia*, **2010**, 53, 1341-8	10.3	115
422	Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. *Nature Reviews Gastroenterology and Hepatology*, **2018**, 15, 425-439	24.2	114
421	Complications, morbidity and mortality of nonalcoholic fatty liver disease. *Metabolism: Clinical and Experimental*, **2020**, 111S, 154170	12.7	113
420	Relationship between red blood cell distribution width and kidney function tests in a large cohort of unselected outpatients. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2008**, 68, 745-8	2	112
419	Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2006**, 16, 543-9	4.5	112
418	Relationship between ABO blood group and von Willebrand factor levels: from biology to clinical implications. *Thrombosis Journal*, **2007**, 5, 14	5.6	109

417	Cigarette Smoking and Insulin Resistance in Patients with Noninsulin-Dependent Diabetes Mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1997**, 82, 3619-3624	5.6	107
416	Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. *Metabolism: Clinical and Experimental*, **2013**, 62, 392-9	12.7	106
415	Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. *Seminars in Thrombosis and Hemostasis*, **2009**, 35, 277-87	5.3	106
414	The use of recombinant activated FVII in postpartum hemorrhage. *Clinical Obstetrics and Gynecology*, **2010**, 53, 219-27	1.7	106
413	NAFLD as a driver of chronic kidney disease. *Journal of Hepatology*, **2020**, 72, 785-801	13.4	104
412	Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2014**, 34, 1155-61	9.4	99
411	Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. *Diabetes Care*, **2014**, 37, 1729-36	14.6	98
410	Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. *Liver International*, **2016**, 36, 1563-1579	7.9	96
409	Elevated serum uric acid concentrations independently predict cardiovascular mortality in type 2 diabetic patients. *Diabetes Care*, **2009**, 32, 1716-20	14.6	94
408	Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. *Gut*, **2020**, 69, 1545-1547	19.2	93
407	Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. *Clinical Endocrinology*, **2004**, 61, 700-3	3.4	93
406	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. *European Journal of Heart Failure*, **2017**, 19, 54-65	12.3	92
405	Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. *Diabetic Medicine*, **2005**, 22, 999-1004	3.5	92
404	Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. *Nature Reviews Gastroenterology and Hepatology*, **2012**, 9, 372-81	24.2	90
403	Patients with diabetes are at higher risk for severe illness from COVID-19. *Diabetes and Metabolism*, **2020**, 46, 335-337	5.4	84
402	Iron and thrombosis. *Annals of Hematology*, **2008**, 87, 167-73	3	84
401	Mortality from chronic liver diseases in diabetes. *American Journal of Gastroenterology*, **2014**, 109, 1020-5	5.7	83
400	Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 147-57	5.9	83

399	Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. *Metabolism: Clinical and Experimental*, **2017**, 72, 57-65	12.7	80
398	Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. *Clinical Science*, **2013**, 125, 301-9	6.5	80
397	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-5192	3.3	80
396	Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. *Gut*, **2021**, 70, 962-969	19.2	80
395	ABO blood group, hypercoagulability, and cardiovascular and cancer risk. *Critical Reviews in Clinical Laboratory Sciences*, **2012**, 49, 137-49	9.4	76
394	Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease. *Digestive Diseases and Sciences*, **2016**, 61, 1246-67	4	75
393	Non-alcoholic fatty liver disease is associated with carotid artery wall thickness in diet-controlled type 2 diabetic patients. *Journal of Endocrinological Investigation*, **2006**, 29, 55-60	5.2	74
392	Clinical usefulness of measuring red blood cell distribution width on admission in patients with acute coronary syndromes. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 353-7	5.9	70
391	Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease - Atherosclerosis as a Major Player in the Natural Course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-5192	3.3	70
390	Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV. *World Journal of Gastroenterology*, **2016** , 22, 9674-9693	5.6	69
389	Type 2 diabetes mellitus and risk of hepatocellular carcinoma: spotlight on nonalcoholic fatty liver disease. *Annals of Translational Medicine*, **2017**, 5, 270	3.2	68
388	Associations between liver histology and cortisol secretion in subjects with nonalcoholic fatty liver disease. *Clinical Endocrinology*, **2006**, 64, 337-41	3.4	67
387	Help me, Doctor! My D-dimer is raised. *Annals of Medicine*, **2008**, 40, 594-605	1.5	66
386	Nonalcoholic Fatty Liver Disease Is Associated With Ventricular Arrhythmias in Patients With Type 2 Diabetes Referred for Clinically Indicated 24-Hour Holter Monitoring. *Diabetes Care*, **2016**, 39, 1416-23	14.6	66
385	Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. *Diabetes Care*, **2017**, 40, 671-678	14.6	65
384	Relationship between high-sensitivity C-reactive protein levels and liver histology in subjects with non-alcoholic fatty liver disease. *Journal of Hepatology*, **2006**, 45, 879-81; author reply 881-2	13.4	65
383	Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. *Diabetic Medicine*, **2008**, 25, 45-50	3.5	64
382	Liver Steatosis and Its Relation to Plasma Haemostatic Factors in Apparently Healthy Men - Role of the Metabolic Syndrome. *Thrombosis and Haemostasis*, **1996**, 76, 069-073	7	63

381	Extrapulmonary complications of COVID-19: A multisystem disease?. *Journal of Medical Virology*, **2021**, 93, 323-335	19.7	63
380	Serum uric acid and related factors in 500 hospitalized subjects. *Metabolism: Clinical and Experimental*, **1996**, 45, 1557-61	12.7	62
379	Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. *PLoS ONE*, **2015**, 10, e0135329	3.7	61
378	Immune tolerance with rituximab in congenital haemophilia with inhibitors: a systematic literature review based on individual patients' analysis. *Haemophilia*, **2008**, 14, 903-12	3.3	61
377	Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. *Hepatology*, **2016**, 64, 1388-9	11.2	60
376	Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*, **2020**, 158, 1597-1610.e7	13.3	59
375	The white blood cell count: its relationship to plasma insulin and other cardiovascular risk factors in healthy male individuals. *Journal of Internal Medicine*, **1996**, 239, 435-41	10.8	59
374	EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?. *Diabetologia*, **2016**, 59, 1141-4	10.3	59
373	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. *Diabetes and Metabolism*, **2016**, 42, 142-56	5.4	59
372	Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease. *Expert Review of Gastroenterology and Hepatology*, **2015**, 9, 629-50	4.2	57
371	Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis. *Clinical Science*, **2008**, 115, 1-12	6.5	57
370	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. *Gut*, **2022**, 71, 156-162	19.2	56
369	Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. *Metabolism: Clinical and Experimental*, **2015**, 64, 879-87	12.7	55
368	Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2014**, 24, 663-9	4.5	55
367	Elevated levels of interleukin-6 in young adults with type 1 diabetes without clinical evidence of microvascular and macrovascular complications. *Diabetes Care*, **2001**, 24, 956-7	14.6	55
366	The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. *Nature Reviews Gastroenterology and Hepatology*, **2021**, 18, 599-612	24.2	55
365	MAFLD and risk of CKD. *Metabolism: Clinical and Experimental*, **2021**, 115, 154433	12.7	55
364	Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. *BMJ, The*, **2018**, 362, k2734	3.9	54

363	Association between nonalcoholic liver disease and chronic kidney disease: an ultrasound analysis from NHANES 1988-1994. *American Journal of Nephrology*, **2012**, 36, 466-71	4.6	54
362	Prevalence of neuropathy in type 2 diabetic patients and its association with other diabetes complications: The Verona Diabetic Foot Screening Program. *Journal of Diabetes and Its Complications*, **2015**, 29, 1066-70	3.2	53
361	Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?. *Endocrine*, **2016**, 51, 211-21	4	53
360	Relation of elevated serum uric acid levels to incidence of atrial fibrillation in patients with type 2 diabetes mellitus. *American Journal of Cardiology*, **2013**, 112, 499-504	3	53
359	Prognostic Impact of Diabetes on Long-term Survival Outcomes in Patients With Heart Failure: A Meta-analysis. *Diabetes Care*, **2017**, 40, 1597-1605	14.6	52
358	Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?. *Journal of Endocrinological Investigation*, **2015**, 38, 817-25	5.2	52
357	Aortic and mitral annular calcifications are predictive of all-cause and cardiovascular mortality in patients with type 2 diabetes. *Diabetes Care*, **2012**, 35, 1781-6	14.6	52
356	25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease. *American Journal of Nephrology*, **2009**, 30, 64-72	4.6	52
355	Low 25-hydroxyvitamin D level is independently associated with non-alcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2013**, 23, 792-8	4.5	51
354	Laboratory, clinical and therapeutic aspects of acquired hemophilia A. *Clinica Chimica Acta*, **2008**, 395, 14-8	6.2	51
353	Plasma PAI-1 levels are increased in patients with nonalcoholic steatohepatitis. *Diabetes Care*, **2007**, 30, e31-2	14.6	51
352	Association Between Primary Hypothyroidism and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. *Thyroid*, **2018**, 28, 1270-1284	6.2	50
351	Variability of body weight, pulse pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. *Diabetes/Metabolism Research and Reviews*, **2008**, 24, 624-8	7.5	50
350	Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. *Metabolites*, **2021**, 11,	5.6	50
349	Vitamin D, thrombosis, and hemostasis: more than skin deep. *Seminars in Thrombosis and Hemostasis*, **2012**, 38, 114-24	5.3	49
348	Epidemiological association between uric acid concentration in plasma, lipoprotein(a), and the traditional lipid profile. *Clinical Cardiology*, **2010**, 33, E76-80	3.3	49
347	Increased prevalence of chronic kidney disease in patients with Type 1 diabetes and non-alcoholic fatty liver. *Diabetic Medicine*, **2012**, 29, 220-6	3.5	48
346	Glycated hemoglobin (HbA1c): old dogmas, a new perspective?. *Clinical Chemistry and Laboratory Medicine*, **2010**, 48, 609-14	5.9	48

345	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. *Metabolism: Clinical and Experimental*, **2018**, 87, 1-12	12.7	48
344	Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. *Nutrition, Metabolism and Cardiovascular Diseases*, **2010**, 20, 583-90	4.5	47
343	Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?. *International Journal of Molecular Sciences*, **2016**, 17, 217	6.3	47
342	Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons?. *Advances in Clinical Chemistry*, **2010**, 50, 47-63	5.8	46
341	Relation between soluble adhesion molecules and insulin sensitivity in type 2 diabetic individuals: role of adipose tissue. *Diabetes Care*, **2001**, 24, 1961-6	14.6	46
340	PNPLA3 rs738409 is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. *Liver International*, **2020**, 40, 107-119	7.9	46
339	The metabolic syndrome and the risk of arterial and venous thrombosis. *Thrombosis Research*, **2008**, 122, 727-35	8.2	45
338	Cardiovascular and systemic risk in nonalcoholic fatty liver disease - atherosclerosis as a major player in the natural course of NAFLD. *Current Pharmaceutical Design*, **2013**, 19, 5177-92	3.3	45
337	Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. *Journal of Endocrinological Investigation*, **2012**, 35, 215-8	5.2	44
336	Hemostatic abnormalities in endocrine and metabolic disorders. *European Journal of Endocrinology*, **2010**, 162, 439-51	6.5	44
335	Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients. *Clinical Endocrinology*, **2008**, 68, 481-4	3.4	44
334	Acquired factor VIII inhibitors in oncohematology: a systematic review. *Critical Reviews in Oncology/Hematology*, **2008**, 66, 194-9	7	44
333	The effect of iron depletion on chronic hepatitis C virus infection. *Hepatology International*, **2008**, 2, 335-40	8.6	44
332	Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated meta-analysis. *Liver International*, **2019**, 39, 758-769	7.9	43
331	NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	43
330	Erythrocyte mechanical fragility is increased in patients with type 2 diabetes. *European Journal of Internal Medicine*, **2012**, 23, 150-3	3.9	43
329	Effect of lovastatin on primary prevention of cardiovascular events in mild CKD and kidney function loss: a post hoc analysis of the Air Force/Texas Coronary Atherosclerosis Prevention Study. *American Journal of Kidney Diseases*, **2010**, 55, 42-9	7.4	43
328	Pathogenesis, clinical and laboratory aspects of thrombosis in cancer. *Journal of Thrombosis and Thrombolysis*, **2007**, 24, 29-38	5.1	43

327	Prevalence of Cardiovascular Autonomic Neuropathy in a Cohort of Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS). *Diabetes Care*, **2015**, 38, 1487-93	14.6	42
326	A "systems medicine" approach to the study of non-alcoholic fatty liver disease. *Digestive and Liver Disease*, **2016**, 48, 333-42	3.3	42
325	Vaccination, squalene and anti-squalene antibodies: facts or fiction?. *European Journal of Internal Medicine*, **2010**, 21, 70-3	3.9	42
324	Effect of moderate aerobic exercise on sympatho-vagal balance in Type 2 diabetic patients. *Diabetic Medicine*, **2007**, 24, 370-6	3.5	42
323	Predictors of insulin sensitivity in Type 2 diabetes mellitus. *Diabetic Medicine*, **2002**, 19, 535-42	3.5	42
322	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. *Diabetes and Metabolism*, **2020**, 46, 427-441	5.4	42
321	Diagnosis and management of nonalcoholic fatty liver disease and its hemostatic/thrombotic and vascular complications. *Seminars in Thrombosis and Hemostasis*, **2013**, 39, 214-28	5.3	41
320	Higher HDL cholesterol levels are associated with a lower incidence of chronic kidney disease in patients with type 2 diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 580-6	4.5	41
319	Reduced von Willebrand factor-cleaving protease levels in secondary thrombotic microangiopathies and other diseases. *Seminars in Thrombosis and Hemostasis*, **2007**, 33, 787-97	5.3	40
318	Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. *International Journal of Cardiology*, **2016**, 225, 387-391	3.2	39
317	Prognostic Impact of Diabetes and Prediabetes on Survival Outcomes in Patients With Chronic Heart Failure: A Post-Hoc Analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) Trial. *Journal of the American Heart Association*, **2017**, 6,	6	39
316	Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review. *Clinical and Applied Thrombosis/Hemostasis*, **2011**, 17, 387-92	3.3	39
315	Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. *Seminars in Thrombosis and Hemostasis*, **2010**, 36, 41-8	5.3	39
314	High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. *Diabetes Care* , **2011**, 34, 1038-40	14.6	39
313	Fasting serum insulin in relation to components of the metabolic syndrome in European healthy men: the European Fat Distribution Study. *Metabolism: Clinical and Experimental*, **1995**, 44, 35-40	12.7	39
312	Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. *PLoS ONE*, **2014**, 9, e88371	3.7	39
311	Hyperuricemia in patients with chronic plaque psoriasis. *Journal of the American Academy of Dermatology*, **2014**, 70, 127-30	4.5	38
310	Hemophilia and cancer: a new challenge for hemophilia centers. *Cancer Treatment Reviews*, **2009**, 35, 374-7	14.4	38

309	Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 578-588	18.8	37
308	Circulating Markers of Liver Function and Cardiovascular Disease Risk. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2015**, 35, 2290-6	9.4	36
307	Interpatient phenotypic inconsistency in severe congenital hemophilia: a systematic review of the role of inherited thrombophilia. *Seminars in Thrombosis and Hemostasis*, **2009**, 35, 307-12	5.3	36
306	Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). *American Journal of Cardiology*, **2010**, 106, 564-8	3	36
305	Glycated haemoglobin is inversely related to serum vitamin D levels in type 2 diabetic patients. *PLoS ONE*, **2013**, 8, e82733	3.7	36
304	Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1055-62	5.9	35
303	Effect of simvastatin on kidney function loss in patients with coronary heart disease: findings from the Scandinavian Simvastatin Survival Study (4S). *Atherosclerosis*, **2009**, 205, 202-6	3.1	34
302	Cigarette smoking and plasma total homocysteine levels in young adults with type 1 diabetes. *Diabetes Care*, **2000**, 23, 524-8	14.6	34
301	Clinical relevance of liver histopathology and different histological classifications of NASH in adults. *Expert Review of Gastroenterology and Hepatology*, **2018**, 12, 351-367	4.2	34
300	Epidemiology and pathophysiology of the association between NAFLD and metabolically healthy or metabolically unhealthy obesity. *Annals of Hepatology*, **2020**, 19, 359-366	3.1	33
299	Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: The Study of Health in Pomerania (SHIP). *Atherosclerosis*, **2016**, 245, 123-31	3.1	33
298	Epidemiological association between fasting plasma glucose and shortened APTT. *Clinical Biochemistry*, **2009**, 42, 118-20	3.5	33
297	Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes?. *Nutrition, Metabolism and Cardiovascular Diseases*, **2009**, 19, 334-9	4.5	33
296	Association between 25-hydroxyvitamin D deficiency and cardiovascular disease in type 2 diabetic patients with mild kidney dysfunction. *Nephrology Dialysis Transplantation*, **2008**, 23, 269-74	4.3	33
295	Lower levels of 25-hydroxyvitamin D3 are associated with a higher prevalence of microvascular complications in patients with type 2 diabetes. *BMJ Open Diabetes Research and Care*, **2015**, 3, e000058	4.5	32
294	Elevated plasma levels of soluble receptors of TNF-alpha and their association with smoking and microvascular complications in young adults with type 1 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 3805-8	5.6	32
293	Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. *Atherosclerosis*, **1994**, 106, 139-47	3.1	32
292	Prevalence of thyroid autoimmunity and subclinical hypothyroidism in persons with chronic kidney disease not requiring chronic dialysis. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1367-71	5.9	31

291	Genetic and biochemical heterogeneity of cardiac troponins: clinical and laboratory implications. *Clinical Chemistry and Laboratory Medicine*, **2009**, 47, 1183-94	5.9	31
290	Psychological distress, self-efficacy and glycemic control in type 2 diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2017**, 27, 300-306	4.5	30
289	Nonalcoholic fatty liver disease is associated with an increased prevalence of distal symmetric polyneuropathy in adult patients with type 1 diabetes. *Journal of Diabetes and Its Complications*, **2017**, 31, 1021-1026	3.2	30
288	Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection--Liver: The "Musketeer" in the Spotlight. *International Journal of Molecular Sciences*, **2016**, 17, 355	6.3	30
287	Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. *PLoS ONE*, **2017**, 12, e0185459	3.7	29
286	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. *Diabetes and Metabolism*, **2021**, 47, 101215	5.4	29
285	Mortality from infectious diseases in diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2018**, 28, 444-450	4.5	28
284	Obesity: Metabolically healthy obesity and NAFLD. *Nature Reviews Gastroenterology and Hepatology*, **2016**, 13, 442-4	24.2	28
283	Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis. *Nephrology Dialysis Transplantation*, **2008**, 23, 2879-83	4.3	28
282	Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 903-913	18.8	28
281	Prognostic impact of in-hospital hyperglycemia in hospitalized patients with acute heart failure: Results of the IN-HF (Italian Network on Heart Failure) Outcome registry. *International Journal of Cardiology*, **2016**, 203, 587-93	3.2	27
280	Abnormal serum alanine aminotransferase levels are associated with impaired insulin sensitivity in young women with polycystic ovary syndrome. *Journal of Endocrinological Investigation*, **2009**, 32, 695-700	5.2	27
279	Hypoadiponectinemia is closely associated with nonalcoholic hepatic steatosis in obese subjects. *Diabetes Care*, **2004**, 27, 2085-6	14.6	27
278	Liver fibrosis by FibroScan independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes. *Liver International*, **2020**, 40, 347-354	7.9	27
277	Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?. *Digestive and Liver Disease*, **2019**, 51, 462-470	3.3	26
276	Increased aortic pulse wave velocity as measured by echocardiography is strongly associated with poor prognosis in patients with heart failure. *Journal of the American Society of Echocardiography*, **2013**, 26, 714-20	5.8	26
275	Anaemia, independent of chronic kidney disease, predicts all-cause and cardiovascular mortality in type 2 diabetic patients. *Atherosclerosis*, **2010**, 210, 575-80	3.1	26
274	Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients. *Journal of Thrombosis and Thrombolysis*, **2009**, 28, 362-5	5.1	26

273	Nonalcoholic fatty liver disease and increased risk of 1-year all-cause and cardiac hospital readmissions in elderly patients admitted for acute heart failure. *PLoS ONE*, **2017**, 12, e0173398	3.7	26
272	Hyperuricemia is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. *Journal of Endocrinological Investigation*, **2016**, 39, 159-67	5.2	25
271	Associations between liver histology and carotid intima-media thickness in patients with nonalcoholic fatty liver disease. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, 2687-8	9.4	25
270	Factors associated with significant liver steatosis and fibrosis as assessed by transient elastography in patients with one or more components of the metabolic syndrome. *Journal of Diabetes and Its Complications*, **2016**, 30, 1347-53	3.2	25
269	Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. *Metabolism: Clinical and Experimental*, **2019**, 96, 56-65	12.7	24
268	Global epidemiology of lean non-alcoholic fatty liver disease: A systematic review and meta-analysis. *Journal of Gastroenterology and Hepatology (Australia)*, **2020**, 35, 2041-2050	4	24
267	Nonalcoholic fatty liver disease and reduced serum vitamin D(3) levels. *Metabolic Syndrome and Related Disorders*, **2013**, 11, 217-28	2.6	24
266	Extra-skeletal effects of vitamin D deficiency in chronic kidney disease. *Annals of Medicine*, **2011**, 43, 273-82	1.5	24
265	Anaphylaxis in patients with congenital bleeding disorders and inhibitors. *Blood Coagulation and Fibrinolysis*, **2009**, 20, 225-9	1	24
264	Sudden cardiac death: prevalence, pathogenesis, and prevention. *Annals of Medicine*, **2008**, 40, 360-75	1.5	24
263	Relationship between thyroid status and renal function in a general population of unselected outpatients. *Clinical Biochemistry*, **2008**, 41, 625-7	3.5	24
262	Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. *Trends in Endocrinology and Metabolism*, **2021**, 32, 500-514	8.8	24
261	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. *Hepatology*, **2019**, 70, 142-153	11.2	23
260	Optimal therapy for reduction of lipoprotein(a). *Journal of Clinical Pharmacy and Therapeutics*, **2012** , 37, 1-3	2.2	23
259	Glomerular filtration rate, albuminuria and risk of cardiovascular and all-cause mortality in type 2 diabetic individuals. *Nutrition, Metabolism and Cardiovascular Diseases*, **2011**, 21, 294-301	4.5	23
258	Plasma fibrinogen in relation to serum insulin, smoking habits and adipose tissue fatty acids in healthy men. *European Journal of Clinical Investigation*, **1994**, 24, 126-30	4.6	23
257	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. *Digestive and Liver Disease*, **2019**, 51, 1586-1592	3.3	22
256	The role of serum uric acid in cardiovascular disease in type 2 diabetic and non-diabetic subjects: a narrative review. *Journal of Endocrinological Investigation*, **2011**, 34, 881-6	5.2	22

255	Relationship of nonalcoholic hepatic steatosis to overnight low-dose dexamethasone suppression test in obese individuals. *Clinical Endocrinology*, **2004**, 61, 711-5	3.4	22
254	Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. *Metabolites*, **2020**, 11,	5.6	22
253	Increased red blood cell distribution width (RDW) is associated with higher glycosylated hemoglobin (HbA1c) in the elderly. *Clinical Laboratory*, **2014**, 60, 2095-8	2	22
252	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. *Diabetes and Metabolism*, **2019**, 45, 480-487	5.4	22
251	Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 375-388	6.1	22
250	Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease. *Diagnostics*, **2021**, 11,	3.8	22
249	A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. *Metabolic Syndrome and Related Disorders*, **2015**, 13, 235-8	2.6	21
248	Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. *Hepatology*, **2005**, 42, 974-5; discussion 975	11.2	21
247	Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. *Diabetes and Metabolism*, **2020**, 46, 296-303	5.4	21
246	Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2018**, 38, 2854-2861	9.4	21
245	Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. *Metabolism: Clinical and Experimental* , **2018**, 83, 205-215	12.7	20
244	Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. *International Journal of Cardiology*, **2018**, 265, 162-168	3.2	20
243	Usefulness of subclinical left ventricular midwall dysfunction to predict cardiovascular mortality in patients with type 2 diabetes mellitus. *American Journal of Cardiology*, **2014**, 113, 1409-14	3	20
242	Screening and therapeutic management of lipoprotein(a) excess: review of the epidemiological evidence, guidelines and recommendations. *Clinica Chimica Acta*, **2011**, 412, 797-801	6.2	20
241	Comparison of two creatinine-based estimating equations in predicting all-cause and cardiovascular mortality in patients with type 2 diabetes. *Diabetes Care*, **2012**, 35, 2347-53	14.6	20
240	Relationship between abnormal microvolt T-wave alternans and poor glycemic control in type 2 diabetic patients. *PACE - Pacing and Clinical Electrophysiology*, **2007**, 30, 1267-72	1.6	20
239	Relationship between gamma-glutamyltransferase, lipids and lipoprotein(a) in the general population. *Clinica Chimica Acta*, **2007**, 384, 163-6	6.2	20
238	What's new in NAFLD pathogenesis, biomarkers and treatment?. *Nature Reviews Gastroenterology and Hepatology*, **2020**, 17, 70-71	24.2	20

237	Early impairment in left ventricular longitudinal systolic function is associated with an increased risk of incident atrial fibrillation in patients with type 2 diabetes. *Journal of Diabetes and Its Complications*, **2017**, 31, 413-418	3.2	19
236	Low-grade endotoxemia, gut permeability and platelet activation in patients with impaired fasting glucose. *Nutrition, Metabolism and Cardiovascular Diseases*, **2017**, 27, 890-895	4.5	19
235	Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. *Diabetes and Metabolism*, **2020**, 46, 505-507	5.4	19
234	The aspartate aminotransferase-to-alanine aminotransferase ratio predicts all-cause and cardiovascular mortality in patients with type 2 diabetes. *Medicine (United States)*, **2016**, 95, e4821	1.8	19
233	Stereotactic body radiotherapy for lung oligometastases impacts on systemic treatment-free survival: a cohort study. *Medical Oncology*, **2018**, 35, 121	3.7	19
232	A laboratory standpoint on the role of hemoglobin A1c for the diagnosis of diabetes in childhood: more doubts than certainties?. *Pediatric Diabetes*, **2011**, 12, 183-6	3.6	19
231	The use of recombinant factor VIIa in liver diseases. *Blood Coagulation and Fibrinolysis*, **2008**, 19, 341-8	1	19
230	Vitamin D deficiency among Italian children. *Cmaj*, **2007**, 177, 1529-30; author reply 1530	3.5	19
229	Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables. *Journal of Hypertension*, **1995**, 13, 659-66	1.9	19
228	Increased prevalence of cardiovascular disease in Type 1 diabetic patients with non-alcoholic fatty liver disease. *Journal of Endocrinological Investigation*, **2012**, 35, 535-40	5.2	19
227	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. *Gut*, **2021**,	19.2	19
226	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. *Journal of Hepatology*, **2019**, 71, 802-810	13.4	18
225	Hemostatic disorders in type 1 diabetes mellitus. *Seminars in Thrombosis and Hemostasis*, **2011**, 37, 58-65	5.3	18
224	Increased pulse pressure independently predicts incident atrial fibrillation in patients with type 2 diabetes. *Diabetes Care*, **2012**, 35, 2337-9	14.6	18
223	Relationship between serum bilirubin and kidney function in non-diabetic and diabetic individuals. *Kidney International*, **2009**, 75, 863	9.9	18
222	Pioglitazone in nonalcoholic steatohepatitis. *New England Journal of Medicine*, **2007**, 356, 1067; author reply 1068-9	59.2	18
221	Relationship of non-alcoholic hepatic steatosis to cortisol secretion in diet-controlled Type 2 diabetic patients. *Diabetic Medicine*, **2005**, 22, 1146-50	3.5	18
220	Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. *Journal of Gastroenterology and Hepatology (Australia)*, **2020**, 35, 1057-1064	4	18

219	Global multi-stakeholder endorsement of the MAFLD definition.. *The Lancet Gastroenterology and Hepatology*, **2022**,	18.8	18
218	Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. *Diabetes and Metabolism*, **2019**, 45, 536-544	5.4	17
217	Extracorporeal immunoadsorption for the treatment of coagulation inhibitors. *Seminars in Thrombosis and Hemostasis*, **2009**, 35, 76-80	5.3	17
216	Dark chocolate: consumption for pleasure or therapy?. *Journal of Thrombosis and Thrombolysis*, **2009**, 28, 482-8	5.1	17
215	Inherited platelet disorders. *Clinica Chimica Acta*, **2008**, 387, 1-8	6.2	17
214	The significance of evaluating conventional inflammatory markers in Von Willebrand factor measurement. *Clinica Chimica Acta*, **2007**, 381, 167-70	6.2	17
213	Black esophagus syndrome associated with diabetic ketoacidosis. *World Journal of Clinical Cases*, **2016**, 4, 56-9	1.6	17
212	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. *Diabetes and Metabolism*, **2019**, 45, 347-355	5.4	17
211	Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. *Hepatology*, **2019**, 70, 812-823	11.2	16
210	PNPLA3 I148M gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. *Liver International*, **2020**, 40, 1130-1141	7.9	16
209	Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. *Diabetes and Metabolism*, **2020**, 46, 150-157	5.4	16
208	The mean platelet volume is significantly associated with higher glycated hemoglobin in a large population of unselected outpatients. *Primary Care Diabetes*, **2015**, 9, 226-30	2.4	15
207	Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. *Medicine (United States)*, **2016**, 95, e2760	1.8	15
206	Mitral Regurgitation and Increased Risk of All-Cause and Cardiovascular Mortality in Patients with Type 2 Diabetes. *American Journal of Medicine*, **2017**, 130, 70-76.e1	2.4	15
205	Prevention and treatment of nonalcoholic fatty liver disease. *Digestive and Liver Disease*, **2010**, 42, 331-40	3.3	15
204	Monitoring glycaemic control: is there evidence for appropriate use of routine measurement of glycated haemoglobin?. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45, 1065-7	5.9	15
203	Ginkgo biloba, inflammation and lipoprotein(a). *Atherosclerosis*, **2007**, 195, 417-8; author reply 419-22	3.1	15
202	Chronic cigarette smoking is associated with increased plasma circulating intercellular adhesion molecule 1 levels in young type 1 diabetic patients. *Diabetes Care*, **1999**, 22, 1871-4	14.6	15

201	Nonalcoholic Fatty Liver Disease and Estimated Insulin Resistance in Obese Youth: A Mendelian Randomization Analysis. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	15
200	Hyperuricemia is associated with an increased prevalence of paroxysmal atrial fibrillation in patients with type 2 diabetes referred for clinically indicated 24-h Holter monitoring. *Journal of Endocrinological Investigation*, **2018**, 41, 223-231	5.2	14
199	Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. *Liver International*, **2019**, 39, 2317-2329	7.9	14
198	Usefulness of the triglyceride to high-density lipoprotein cholesterol ratio for predicting mortality risk in type 2 diabetes: role of kidney dysfunction. *Atherosclerosis*, **2010**, 212, 287-91	3.1	14
197	Procalcitonin values after dialysis is closely related to type of dialysis membrane. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2009**, 69, 703-7	2	14
196	The red blood cell distribution width is associated with serum levels of thyroid stimulating hormone in the general population. *International Journal of Laboratory Hematology*, **2009**, 31, 581-2	2.5	14
195	Relationship of serum gamma-glutamyltransferase to atherogenic dyslipidemia and glycemic control in type 2 diabetes. *Obesity*, **2009**, 17, 370-4	8	14
194	Relationship between serum phosphate and cardiovascular risk factors in a large cohort of adult outpatients. *Diabetes Research and Clinical Practice*, **2009**, 84, e3-5	7.4	14
193	Effect of hemodialysis on traditional and innovative cardiac markers. *Journal of Clinical Laboratory Analysis*, **2008**, 22, 59-65	3	14
192	Concordance between MAFLD and NAFLD diagnostic criteria in 'real-world' data. *Liver International*, **2020**, 40, 2879-2880	7.9	14
191	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 743-753	18.8	14
190	Prevalence of diabetes across different immigrant groups in North-eastern Italy. *Nutrition, Metabolism and Cardiovascular Diseases*, **2015**, 25, 924-30	4.5	13
189	Inappropriate left ventricular mass independently predicts cardiovascular mortality in patients with type 2 diabetes. *International Journal of Cardiology*, **2013**, 168, 4953-6	3.2	13
188	Hemostatic and fibrinolytic abnormalities in polycystic ovary syndrome. *Seminars in Thrombosis and Hemostasis*, **2014**, 40, 600-18	5.3	13
187	Risk of cardiovascular disease and chronic kidney disease in diabetic patients with non-alcoholic fatty liver disease: just a coincidence?. *Journal of Endocrinological Investigation*, **2011**, 34, 544-51	5.2	13
186	Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. *Clinical Liver Disease*, **2021**, 17, 19-22	2.2	13
185	Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 1601-1608	4.5	12
184	Antithrombotic prophylaxis in patients with von Willebrand disease undergoing major surgery: when is it necessary?. *Journal of Thrombosis and Thrombolysis*, **2009**, 28, 215-9	5.1	12

183	Pasireotide in Cushing's disease. *New England Journal of Medicine*, **2012**, 366, 2134; author reply 2134-5	59.2	12
182	Non-alcoholic fatty liver disease as a determinant of cardiovascular disease. *Atherosclerosis*, **2007**, 190, 18-9; author reply 20-1	3.1	12
181	Increase in circulating products of lipid peroxidation in smokers with IDDM. *Diabetes Care*, **1996**, 19, 1233-66	14	12
180	The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. *Lancet, The*, **2021**,	40	12
179	Pancreatic fat accumulation and its relationship with liver fat content and other fat depots in obese individuals. *Journal of Endocrinological Investigation*, **2012**, 35, 748-53	5.2	12
178	Is Nonalcoholic Fatty Liver Disease Not a Risk Factor for Cardiovascular Disease: Not Yet Time for a Change of Heart. *Hepatology*, **2020**, 71, 1867-1869	11.2	11
177	Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels. *BMJ Open Diabetes Research and Care*, **2020**, 8,	4.5	11
176	Evidence of left atrial remodeling and left ventricular diastolic dysfunction in type 2 diabetes mellitus with preserved systolic function. *Nutrition, Metabolism and Cardiovascular Diseases*, **2016**, 26, 1026-1032	4.5	11
175	Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease. *Hepatology*, **2011**, 53, 375	11.2	11
174	Relationship between early diastolic dysfunction and abnormal microvolt T-wave alternans in patients with type 2 diabetes. *Circulation: Cardiovascular Imaging*, **2011**, 4, 408-14	3.9	11
173	Prevalence of folic Acid and vitamin B12 deficiencies in patients with thyroid disorders. *American Journal of the Medical Sciences*, **2008**, 336, 50-2	2.2	11
172	Effect of chronic treatment with lacidipine or lisinopril on intracellular partitioning of glucose metabolism in type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **1999**, 84, 1544-50	5.6	11
171	Effect of metformin on all-cause mortality and major adverse cardiovascular events: An updated meta-analysis of randomized controlled trials. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 699-704	4.5	11
170	Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. *Metabolism: Clinical and Experimental*, **2018**, 85, 305-312	12.7	11
169	Adiponectin and migraine: systematic review of clinical evidence. *Neurological Sciences*, **2014**, 35, 1167-71	3.5	10
168	Tomatoes, lycopene-containing foods and cancer risk. *British Journal of Cancer*, **2011**, 104, 1234-5	8.7	10
167	Hemostatic and fibrinolytic abnormalities in endocrine diseases: a narrative review. *Seminars in Thrombosis and Hemostasis*, **2009**, 35, 605-12	5.3	10
166	Risk of all-cause and cardiovascular mortality in patients with chronic liver disease. *Gut*, **2011**, 60, 1602-3; author reply 1603-4	19.2	10

165	Prophylaxis in von Willebrand disease. *Annals of Hematology*, **2007**, 86, 699-704	3	10
164	Measurement of microvolt T-wave alternans, a new arrhythmic risk stratification test, in Type 2 diabetic patients without clinical cardiovascular disease. *Diabetic Medicine*, **2006**, 23, 207-10	3.5	10
163	Relationship between fasting insulin and cardiovascular risk factors is already present in young men: the Verona Young Men Atherosclerosis Risk Factors Study. *European Journal of Clinical Investigation*, **1997**, 27, 248-54	4.6	10
162	Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. *Frontiers in Endocrinology*, **2021**, 12, 604100	5.7	10
161	Non-alcoholic fatty liver disease as driving force in coronary heart disease?. *Gut*, **2017**, 66, 213-214	19.2	9
160	Relationship between increased left atrial volume and microvascular complications in patients with type 2 diabetes. *Journal of Diabetes and Its Complications*, **2015**, 29, 822-8	3.2	9
159	Relationship between gamma-glutamyltransferase, fasting plasma glucose, and triglycerides in the general population. *Clinical Chemistry*, **2007**, 53, 1866-7; author reply 1869-70	5.5	9
158	The International Diabetes Federation definition of the metabolic syndrome independently predicts future cardiovascular events in Type 2 diabetic patients. The Valpolicella Heart Diabetes Study. *Diabetic Medicine*, **2006**, 23, 1270-1	3.5	9
157	Determinants of anaemia in the very elderly: a major contribution from impaired renal function?. *Blood Transfusion*, **2010**, 8, 44-8	3.6	9
156	Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. *Diabetes and Metabolism*, **2020**, 46, 288-295	5.4	9
155	Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease. *Diabetes and Metabolism*, **2021**, 47, 101152	5.4	9
154	Influence of hypertriglyceridemia, hyperbilirubinemia and hemolysis on thrombin generation in human plasma. *Clinical Chemistry and Laboratory Medicine*, **2019**, 57, 1784-1789	5.9	8
153	Eosinophilia and first-line coagulation testing. *Journal of Thrombosis and Thrombolysis*, **2009**, 28, 90-3	5.1	8
152	Commentary: Liver enzymes and the risk of adverse cardiovascular outcomes--the lower, the better?. *International Journal of Epidemiology*, **2011**, 40, 1539-41	7.8	8
151	Soluble CD40L in young type 1 diabetic individuals without clinical microvascular and macrovascular complications. *Diabetes Care*, **2004**, 27, 1236-7	14.6	8
150	Plasma total homocysteine levels are associated with von Willebrand factor, soluble intercellular adhesion molecule-1, and soluble tumor necrosis factor-alpha receptors in young type 1 diabetic patients without clinical evidence of macrovascular complications. *Diabetes Care*, **2001**, 24, 1496-7	14.6	8
149	Intracellular partition of plasma glucose disposal in hypertensive and normotensive subjects with type 2 diabetes mellitus. *Journal of Clinical Endocrinology and Metabolism*, **2001**, 86, 2073-9	5.6	8
148	Prospective evaluation of non-alcoholic fatty liver disease by elastographic methods of liver steatosis and fibrosis; controlled attenuation parameter and liver stiffness measurements. *Journal of Diabetes and Its Complications*, **2020**, 34, 107512	3.2	8

147	Abnormal liver enzymes in children and infants with COVID-19: A narrative review of case-series studies. *Pediatric Obesity*, **2020**, 15, e12723	4.6	8
146	Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis. *Annals of the Rheumatic Diseases*, **2021**,	2.4	8
145	NAFLD-related mortality: simple hepatic steatosis is not as 'benign' as thought. *Gut*, **2021**, 70, 1212-1213	19.2	8
144	Detection of chronic kidney disease in hospitalized patients: is one estimating glomerular filtration rate equation better than another?. *European Journal of Internal Medicine*, **2011**, 22, 119-20; author reply 120-1	3.9	7
143	Biochemical correlates of lipoprotein(a) in a general adult population. Possible implications for cardiovascular risk assessment. *Journal of Thrombosis and Thrombolysis*, **2009**, 27, 44-7	5.1	7
142	Bilirubin concentration and cardiovascular risk profile. *Liver International*, **2009**, 29, 315-6	7.9	7
141	High-sensitivity C-reactive protein, obesity, and subclinical atherosclerosis: implications of JUPITER from the MESA study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2011**, 31, 1251-2	9.4	7
140	The effect of combined calcium and cholecalciferol supplementation on bone mineral density in elderly women with moderate chronic kidney disease. *Clinical Nephrology*, **2012**, 77, 358-65	2.1	7
139	Serum leptin concentrations in young smokers with type 1 diabetes. *Diabetes Care*, **2001**, 24, 793	14.6	7
138	ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis. *American Journal of Gastroenterology*, **2020**, 115, 1544	0.7	7
137	Non-alcoholic fatty liver disease in obese children and adolescents: a role for nutrition?. *European Journal of Clinical Nutrition*, **2021**,	5.2	7
136	Echocardiographically Derived Pulse Wave Velocity and Diastolic Dysfunction Are Associated with an Increased Incidence of Atrial Fibrillation in Patients with Systolic Heart Failure. *Echocardiography* , **2016**, 33, 1024-31	1.5	7
135	Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. *Diabetes, Obesity and Metabolism*, **2021**,	6.7	7
134	Association between subclinical left ventricular systolic dysfunction and glycemic control in asymptomatic type 2 diabetic patients with preserved left ventricular function. *Journal of Diabetes and Its Complications*, **2017**, 31, 1035-1040	3.2	6
133	Effect of aspirin on renal disease progression in patients with type 2 diabetes: A multicenter, double-blind, placebo-controlled, randomized trial. The renaL disEase progression by aspirin in diabetic pAtients (LEDA) trial. Rationale and study design. *American Heart Journal*, **2017**, 189, 120-127	4.9	6
132	Relation between plasma ceramides and cardiovascular death in chronic heart failure: A subset analysis of the GISSI-HF trial. *ESC Heart Failure*, **2020**, 7, 3288	3.7	6
131	Venous thromboembolism in chronic liver disease. *Seminars in Thrombosis and Hemostasis*, **2011**, 37, 66-76	5.3	6
130	Plasma gamma-glutamyl transferase activity predicts homocysteine concentration in a large cohort of unselected outpatients. *Internal Medicine*, **2008**, 47, 705-7	1.1	6

129	Relationship between mean platelet volume and biochemical components of the metabolic syndrome. *Clinical Drug Investigation*, **2007**, 27, 731-2; author reply 732-3	3.2	6
128	Lipoprotein(a), thrombophilia and venous thrombosis. *Acta Haematologica*, **2007**, 117, 246-7	2.7	6
127	Plasma factor VII and its relation to adipose tissue fatty acids and other atherogenic risk factors in healthy men. *European Journal of Clinical Investigation*, **1996**, 26, 247-53	4.6	6
126	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.. *The Lancet Gastroenterology and Hepatology*, **2022**,	18.8	6
125	Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Type 2 Diabetes: A New Imaging Possibility and a New Biomarker. *Calcified Tissue International*, **2021**, 108, 231-239	3.9	6
124	Is COVID-19 lockdown associated with vitamin D deficiency?. *European Journal of Public Health*, **2021**, 31, 278-279	2.1	6
123	Relation of elevated serum uric acid levels to first-degree heart block and other cardiac conduction defects in hospitalized patients with type 2 diabetes. *Journal of Diabetes and Its Complications*, **2017**, 31, 1691-1697	3.2	5
122	Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 1820-1825	4.5	5
121	Inherited and acquired risk factors for arterial ischemic stroke in childhood. *Journal of Thrombosis and Thrombolysis*, **2009**, 27, 239-48	5.1	5
120	Safety of recombinant activated factor VII in randomized clinical trials. *New England Journal of Medicine*, **2011**, 364, 575; author reply 575-6	59.2	5
119	Plasma D-dimer in the diagnosis of acute aortic dissection. *European Heart Journal*, **2008**, 29, 1207; author reply 1207-8	9.5	5
118	Relationship between lipoprotein(a) and thyroid function status in the general population. *Archives of Medical Research*, **2007**, 38, 905-6; author reply 907-8	6.6	5
117	Effect of serum gamma-glutamyltransferase and obesity on the risk of dyslipidemia and poor glycemic control in type 2 diabetic patients: cross-sectional findings from the Verona Diabetes Study. *Clinical Chemistry*, **2007**, 53, 1867-9; author reply 1869-70	5.5	5
116	Association of metabolic dysfunction-associated fatty liver disease with kidney disease.. *Nature Reviews Nephrology*, **2022**,	14.9	5
115	polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. *British Journal of Nutrition*, **2021**, 126, 813-824	3.6	5
114	Human and molecular genetics shed lights on fatty liver disease and diabetes conundrum. *Endocrinology, Diabetes and Metabolism*, **2020**, 3, e00179	2.7	5
113	Prevalence of hepatic steatosis in patients with type 2 diabetes and response to glucose-lowering treatments. A multicenter retrospective study in Italian specialist care. *Journal of Endocrinological Investigation*, **2021**, 44, 1879-1889	5.2	5
112	Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. *Journal of Gastroenterology and Hepatology (Australia)*, **2020**, 35, 1804-1812	4	4

111	Long-Acting GLP-1 Receptor Agonist Exenatide Influence on the Autonomic Cardiac Sympatho-Vagal Balance. *Journal of the Endocrine Society*, **2018**, 2, 53-62	0.4	4
110	Random plasma glucose measurement may improve the diagnostic specificity of highly sensitive troponin in the emergency department. *International Journal of Cardiology*, **2012**, 155, 172-3	3.2	4
109	Further insights on the relationship between bilirubin and C-reactive protein. *Clinical Chemistry and Laboratory Medicine*, **2012**, 50, 2229-30	5.9	4
108	Non-alcoholic Fatty Liver Disease and Cardiovascular Disease Risk. *Current Cardiovascular Risk Reports*, **2010**, 4, 32-39	0.9	4
107	Detecting of chronic kidney disease in older people by the MDRD and MCQ formulas. *Age and Ageing*, **2008**, 37, 722	3	4
106	Obesity worsens cardiovascular risk profiles independently of hyperinsulinaemia. *Journal of Internal Medicine*, **1997**, 241, 463-70	10.8	4
105	Platelets and lipoprotein(a) in retinal vein occlusion: Mutual targets for aspirin therapy. *Thrombosis and Haemostasis*, **2007**, 97, 1059-1060	7	4
104	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 1926-1936	4.5	4
103	Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD. *Journal of Hepato-Biliary-Pancreatic Sciences*, **2021**, 28, 593-603	2.8	4
102	Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. *British Journal of Nutrition*, **2021**, 1-8	3.6	4
101	Severe hypoglycemia in patients with known diabetes requiring emergency department care: A report from an Italian multicenter study. *Journal of Clinical and Translational Endocrinology*, **2016**, 5, 46-52	2.4	4
100	Association between specific plasma ceramides and high-sensitivity C-reactive protein levels in postmenopausal women with type 2 diabetes. *Diabetes and Metabolism*, **2020**, 46, 326-330	5.4	4
99	The E/e' ratio difference between subjects with type 2 diabetes and controls. A meta-analysis of clinical studies. *PLoS ONE*, **2018**, 13, e0209794	3.7	4
98	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 3257-3270	4.5	4
97	Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 2539-2546	4.5	4
96	Increased aortic stiffness index in patients with type 1 diabetes without cardiovascular disease compared to controls. *Journal of Endocrinological Investigation*, **2019**, 42, 1109-1115	5.2	3
95	Nonalcoholic Fatty Liver Disease and Implications for Older Adults with Diabetes. *Clinics in Geriatric Medicine*, **2020**, 36, 527-547	3.8	3
94	PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. *Diabetes and Metabolism*, **2020**, 46, 496-503	5.4	3

93	Vitamin B12, folate, and anemia in old age. *Archives of Internal Medicine*, **2009**, 169, 716		3
92	Haemoglobin A1c and diagnosis of diabetes. Not ready for the prime time?. *Annals of Clinical Biochemistry*, **2012**, 49, 508	2.2	3
91	Uric acid concentration in patient with acute coronary syndrome. *Internal and Emergency Medicine*, **2008**, 3, 409-11	3.7	3
90	Relationship between serum vitamin D and inflammatory markers in the general population: comment on the article by Patel et al. *Arthritis and Rheumatism*, **2008**, 58, 913-4		3
89	Alanine aminotransferase as an independent predictor of incident nonalcoholic fatty liver disease. *Clinical Chemistry*, **2007**, 53, 1159; author reply 1159-61	5.5	3
88	The role of iron in diabetes and its complications: response to Swaminathan et al. *Diabetes Care*, **2007**, 30, e132	14.6	3
87	Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women: response to Juutilainen et al. *Diabetes Care*, **2007**, 30, e51; author reply e52	14.6	3
86	Visceral adipose tissue may mediate the link between non-alcoholic fatty liver disease and endocrine abnormalities. *Journal of Hepatology*, **2006**, 45, 454; author reply 454-6	13.4	3
85	Hypovitaminosis D among unselected medical inpatients and outpatients in Northern Italy. *Clinical Endocrinology*, **2006**, 64, 475	3.4	3
84	Risk of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis: an updated systematic review and meta-analysis of observational studies.. *Journal of Endocrinological Investigation*, **2022**, 1	5.2	3
83	Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week.. *Journal of the American College of Cardiology*, **2022**, 79, 180-191	15.1	3
82	From nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease: is it time for a change of terminology?. *Hepatoma Research*,2020,	4.3	3
81	Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. *Nutrition and Diabetes*, **2021**, 11, 32	4.7	3
80	Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. *European Journal of Gastroenterology and Hepatology*, **2021**, 33, 430-435	2.2	3
79	Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk. *European Heart Journal*, **2020**, 41, 331	9.5	3
78	What's Past Is Prologue: History of Nonalcoholic Fatty Liver Disease. *Metabolites*, **2020**, 10,	5.6	3
77	Association between MBOAT7 rs641738 polymorphism and non-alcoholic fatty liver in overweight or obese children. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 1548-1555	4.5	3
76	Significant liver fibrosis, as assessed by fibroscan, is independently associated with chronic vascular complications of type 2 diabetes: A multicenter study. *Diabetes Research and Clinical Practice*, **2021**, 177, 108884	7.4	3

75	Plasma Bile Acid Profile in Patients with and without Type 2 Diabetes. *Metabolites*, **2021**, 11,	5.6	3
74	Nonalcoholic fatty liver disease, cardiovascular outcomes, and mortality in patients undergoing a coronary angiogram. *Hepatology*, **2016**, 64, 684-5	11.2	3
73	Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes-The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 3464-3473	4.5	3
72	Changes in markers of hepatic steatosis and fibrosis in patients with type 2 diabetes during treatment with glucagon-like peptide-1 receptor agonists. A multicenter retrospective longitudinal study. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 3474-3483	4.5	3
71	Liver fat content, non-alcoholic fatty liver disease, and risk of ischaemic heart disease. *European Heart Journal*, **2018**, 39, 3398	9.5	2
70	Left ventricular chamber dilation and filling pressure may help to categorise patients with type 2 diabetes. *BMJ Open Diabetes Research and Care*, **2018**, 6, e000529	4.5	2
69	Plasma Leptin in Patients at Intermediate to High Cardiovascular Risk With and Without Type 2 Diabetes Mellitus. *Journal of Clinical Laboratory Analysis*, **2017**, 31,	3	2
68	Nonalcoholic fatty liver disease and atherosclerosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2005**, 25, e117; author reply e117-8	9.4	2
67	J-shaped relationship between serum zinc levels and the severity of hepatic necro-inflammation in patients with MAFLD.. *Nutrition, Metabolism and Cardiovascular Diseases*, **2022**,	4.5	2
66	Association between higher serum uric acid levels and plasma N-terminal pro-B-type natriuretic peptide concentrations in patients with coronary artery disease and without overt heart failure.. *International Journal of Cardiology*, **2022**,	3.2	2
65	Associations of liver volume and other markers of hepatic steatosis with all-cause mortality in the general population. *Liver International*, **2021**,	7.9	2
64	Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease.. *Journal of Clinical and Translational Hepatology*, **2022**, 10, 230-237	5.2	2
63	GLP-1 receptor agonists for NAFLD treatment in patients with and without type 2 diabetes: an updated meta-analysis. *Exploration of Medicine*, **2020**, 1, 108-123	1.1	2
62	NAFLD fibrosis score (NFS) can be used in outpatient services to identify chronic vascular complications besides advanced liver fibrosis in type 2 diabetes. *Journal of Diabetes and Its Complications*, **2020**, 34, 107684	3.2	2
61	The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 1822-1831	4.5	2
60	Does high LDL-cholesterol cause cardiovascular disease?. *Expert Review of Clinical Pharmacology*, **2019**, 12, 91	3.8	2
59	Association between lower plasma adiponectin levels and higher plasma thrombin generation parameters in men with type 2 diabetes: role of plasma triglycerides. *Journal of Endocrinological Investigation*, **2021**, 44, 547-555	5.2	2
58	Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. *Nutrition, Metabolism and Cardiovascular Diseases*, **2021**, 31, 552-560	4.5	2

57	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. *EClinicalMedicine*, **2021**, 41, 101145	11.3	2
56	Estimating the real burden of cardiovascular mortality in diabetes. *European Review for Medical and Pharmacological Sciences*, **2019**, 23, 6700-6706	2.9	2
55	Pre-existing type 2 diabetes is associated with increased all-cause death independently of echocardiographic predictors of poor prognosis only in ischemic heart disease. *Nutrition, Metabolism and Cardiovascular Diseases*, **2020**, 30, 2036-2040	4.5	1
54	Further advices on measuring lipoprotein(a) for reducing the residual cardiovascular risk on statin therapy. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, e144-e147	5.9	1
53	Increased aortic stiffness in adults with chronic indeterminate Chagas disease. *PLoS ONE*, **2019**, 14, e0220689	3.7	1
52	Diagnostic significance of haematological testing in patients presenting at the Emergency Department. *Emergency Care Journal*, **2012**, 8, 7	1.2	1
51	Higher random plasma glucose level is associated with increased plasma cardiac troponin in emergency department patients with suspected acute coronary syndrome. *American Journal of Cardiology*, **2012**, 109, 775-6	3	1
50	Relationship between albuminuria and hemoglobin level. *Diabetes Research and Clinical Practice*, **2009**, 86, e62-3	7.4	1
49	Impact of reference category and number of traits in the cluster on risk of coronary heart disease in metabolic syndrome: prospective data from the Bruneck study. *Metabolic Syndrome and Related Disorders*, **2011**, 9, 313-8	2.6	1
48	Relationship between soluble CD40 ligand and gamma-glutamyltransferase concentrations in non-drinking, young Type 1 diabetic individuals. *Diabetic Medicine*, **2008**, 25, 1283-8	3.5	1
47	Glucose challenge test does not predict gestational diabetes mellitus. *Internal Medicine*, **2008**, 47, 1171-4	1.1	1
46	Natriuretic peptides for assessing the prognosis of acute pulmonary embolism. *Chest*, **2008**, 133, 1531	5.3	1
45	Relationship between lipoprotein(a) and fasting plasma glucose in the general population. *European Journal of Clinical Investigation*, **2007**, 37, 826-7	4.6	1
44	Prevalence of Nonalcoholic Fatty Liver Disease and Its Association With Cardiovascular Disease Among Type 2 Diabetic Patients: Response to Schindhelm, Heine, and Diamant. *Diabetes Care*, **2007** , 30, e95-e95	14.6	1
43	Has homocysteine shrunk?. *Clinical Chemistry and Laboratory Medicine*, **2007**, 45, 1419-20	5.9	1
42	Inflammatory variables may mediate the link between low plasma vitamin B6 concentrations and cardiovascular disease in type 2 diabetes. *Nutrition, Metabolism and Cardiovascular Diseases*, **2006**, 16, e9-e10	4.5	1
41	High-Dose Vitamin D Supplementation and Bone Health. *JAMA - Journal of the American Medical Association*, **2020**, 323, 92	27.4	1
40	TA allele of rs2070673 in the CYP2E1 gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease. *Journal of Gastroenterology and Hepatology (Australia)*, **2021**, 36, 2925-2934	4	1

39	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. *Journal of Clinical and Translational Hepatology*, **2021**, 9, 194-202	5.2	1
38	Association between decreasing estimated glomerular filtration rate and risk of cardiac conduction defects in patients with type 2 diabetes. *Diabetes and Metabolism*, **2018**, 44, 473-481	5.4	1
37	Coffee, Atrial Fibrillation, and Circulating Ceramides in Patients with Chronic Heart Failure. *Journal of Agricultural and Food Chemistry*, **2021**, 69, 11236-11245	5.7	1
36	Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed. *Gut*, **2021**,	19.2	1
35	Ultrasonographic intra-abdominal depth and its relation to haemostatic factors in healthy males **1996**, 20, 882-5		1
34	Effects of pioglitazone on cardiovascular events and all-cause mortality in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.. *Nutrition, Metabolism and Cardiovascular Diseases*, **2022**, 32, 529-536	4.5	1
33	Insulin effect on serum potassium and auto-inhibition of insulin secretion is intact in a patient with leprechaunism despite severe impairment of substrates metabolism. *Diabetes/Metabolism Research and Reviews*, **2008**, 24, 205-10	7.5	0
32	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD.. *Metabolism: Clinical and Experimental*, **2021**, 128, 154958	12.7	0
31	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. *Clinical and Translational Gastroenterology*, **2021**, 12, e00321	4.2	0
30	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study.. *Hepatobiliary Surgery and Nutrition*, **2022**, 11, 212-226	2.1	0
29	Interaction of , and Increases Susceptibility to Nonalcoholic Steatohepatitis.. *Journal of Clinical and Translational Hepatology*, **2022**, 10, 219-229	5.2	0
28	Italian guidelines for the treatment of type 2 diabetes.. *Acta Diabetologica*, **2022**, 59, 579	3.9	0
27	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease.. *Frontiers in Medicine*, **2022**, 9, 864570	4.9	0
26	Non-Alcoholic Fatty Liver Disease Is Associated With Reduced Glomerular Filtration Rate in Patients With Chronic Plaque Psoriasis.. *Journal of Cutaneous Medicine and Surgery*, **2021**, 12034754211066906	1.6	0
25	Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. *Diabetes and Metabolism Journal*, **2022**, 46, 391-401	5	0
24	Elastographic parameters of liver steatosis and fibrosis predict independently the risk of incident chronic kidney disease and acute myocardial infarction in patients with type 2 diabetes mellitus. *Journal of Diabetes and Its Complications*, **2022**, 108226	3.2	0
23	Letter: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density-authors' reply. *Alimentary Pharmacology and Therapeutics*, **2019**, 49, 961-962	6.1	
22	Diabetes and NAFLD. *Endocrinology*, **2018**, 1-27	0.1	

21	Reply: To PMID 23504926. *Hepatology*, **2014**, 59, 352	11.2
20	Inter-atrial shunt inversion by the sitting position in a patient with a patent foramen ovale and acute pulmonary embolism. *European Heart Journal*, **2014**, 35, 1032	9.5
19	Predictable impact of the routine implementation of the CKD-EPI equation for estimating glomerular filtration rate by a simulation study. *Rivista Italiana Della Medicina Di Laboratorio*, **2012**, 8, 107-113	1.1
18	Response to NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men *Obesity*, **2009**, 17, 627-627	8
17	Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification. *Clinical Chemistry and Laboratory Medicine*, **2011**, 49, 741	5.9
16	Migraine, valproic acid, and lipoprotein(a). *Pediatric Neurology*, **2009**, 41, 78; author reply 78-9	2.9
15	Arm blood pressure index and lipoprotein(a) in renal transplant recipients. *Transplantation Proceedings*, **2008**, 40, 3499	1.1
14	Risks and benefits of replacing conventional plasma lipids with apolipoprotein measurement. *Acta Cardiologica*, **2009**, 64, 413-4; author reply 414	0.9
13	"Buffalo" hump in nonalcoholic fatty liver disease. *Hepatology*, **2007**, 46, 1311-2; author reply 1312	11.2
12	RESPONSE: LETTER TO THE EDITOR. *PACE - Pacing and Clinical Electrophysiology*, **2008**, 31, 261-261	1.6
11	Carotid atherosclerosis and rheumatoid arthritis. *Annals of Internal Medicine*, **2006**, 145, 231; author reply 231	8
10	NAFLD, Diabetes, and Other Endocrine Diseases: Clinical Implications **2020**, 147-168	
9	PNPLA3 rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. *Journal of Clinical and Translational Hepatology*, **2021**, 000, 000-000	5.2
8	Prognostic Role of Pericardial Fat on the Incidence of Heart Failure. *Journal of the American College of Cardiology*, **2021**, 78, e111	15.1
7	Diabetes and NAFLD. *Endocrinology*, **2018**, 495-521	0.1
6	Diabetes and NAFLD. *Endocrinology*, **2019**, 1-27	0.1
5	Increased red blood cell distribution width and platelet-to-lymphocyte ratio for predicting all-cause mortality in patients with type 2 diabetes and advanced heart failure: a causal association or epiphenomenon?. *Kardiologia Polska*, **2019**, 77, 587-588	0.9
4	Diabetes and NAFLD. *Endocrinology*, **2020**, 495-521	0.1

3	Echocardiographic parameters according to insulin dose in young patients affected by type 1 diabetes. *PLoS ONE*, **2020**, 15, e0244483	3.7
2	NAFLD and Cardiovascular Risk Factors: Implications for Vascular Disease71-83	
1	NAFLD, diabete tipo 2, rischio cardiovascolare?. *L Endocrinologo*, **2018**, 19, 255-259	0